Eli Lilly and Co
LSE:0Q1G
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Eli Lilly and Co (0Q1G) under the Base Case is CHF per share.
Compared with the current market price of 244.9569 CHF, the stock appears .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
What one share is worth in the bear, base and bull cases.
Create a free account · No card needed
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Eli Lilly and Does
Eli Lilly is a pharmaceutical company that discovers, develops, makes, and sells prescription medicines. Its products treat major disease areas such as diabetes, obesity, cancer, immune disorders, and neurological conditions. The company does not sell consumer goods; it sells regulated drugs that patients get through doctors, pharmacies, hospitals, and health plans.
- Headquarters
- United States of America US
- Employees
- 50 000
- IPO date
- Jul 9, 1970
Eli Lilly and has a wide economic moat
Patents and legal protection for its clinical trial data keep competitors from freely copying Lilly’s key medicines, allowing it to earn more than sellers of generic drugs. These protections cover treatments across diabetes, obesity, cancer and immune diseases, spreading its protection across several medicines rather than a single product.
Read the full moat analysis
Revenue & Expenses Breakdown
Eli Lilly and Co
Earnings Waterfall
Eli Lilly and Co
What is the Intrinsic Value of one 0Q1G stock?
The intrinsic value for Eli Lilly and Co (0Q1G) under the Base Case is CHF.
Is 0Q1G stock undervalued or overvalued?
Compared with the current market price of 244.9569 CHF, the stock appears .
